ㅤTake-home message from Bekos 2008, published in European Urology:
This paper aimed to understand the natural progression of Peyronie's disease using ultrasound imaging. Ultrasound was used to follow the progression of plaque size over time, and assess the impact of treatment on plaque size. The study found that the size and shape of plaques tend to remain stable over time, and do not progress to cause severe curvature or erectile dysfunction in most men. Solitary hyperechoic lesions without acoustic shadow had the highest rate (82%) of reduction in size and curvature.
ㅤTake-home message from Gelbard 2013, published in The Journal of Urology:
This paper evaluated the safety, efficacy and tolerability of collagenase clostridium histolyticum (CCH) for the treatment of Peyronie's disease through two clinical trials (IMPRESS I & IMPRESS II). These trials found that treatment with CCH was associated with significant improvement with penile curvature deformity and sexual function compared to placebo. The medication was also well-tolerated with a favourable safety profile.